The outcome of these developments is expected to impact the entire field of antisense technology. Although other companies, including Novopharm Biotech (Winnipeg, Manitoba, Canada), Hybridon ...

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable ...

ribozyme technology, antisense technology, tumor immunotherapy and tumor suppressors, translational research, cancer therapy, gene delivery systems (viral and non-viral), anti-gene therapy ...

Builds on Global Intellectual Property Portfolio to Protect DNAbilize® PlatformHOUSTON, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its ...

Study Progresses to Fourth Higher 90 mg/m2Dose CohortCompelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast ...

“This partnership will combine the category-defining expertise in antisense technology which Stan and n-Lorem have developed, with GondolaBio’s ability to rapidly and efficiently progress ...

Sanofi has entered into a collaboration and license agreement with Alloy Therapeutics to develop an antisense oligonucleotide (ASO) therapy targeting a single, undisclosed central nervous system ...

PORTLAND, IN, UNITED STATES, January 28, 2025 /EINPresswire / -- The RNA based therapeutics has been explored as a promising treatment option for the diseases which are difficult to treat. Development ...

Equities research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a report released on Wednesday. The firm set a “sell” rating on the stock.